source
- ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing StudiesExperts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago↗ source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...Endpoints · 3mo ago↗ source
- STAT+: More political interference at the FDA?A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.STAT · 3mo ago↗ source